

# Claudia Grossi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7569333/publications.pdf>

Version: 2024-02-01

36  
papers

1,756  
citations

304368

22  
h-index

414034

32  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1952  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 236-250.	1.5	205
2	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 584241.	2.2	137
3	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. <i>Journal of Autoimmunity</i> , 2021, 116, 102560.	3.0	127
4	A non- $\beta$ complement-fixing antibody to $\beta$ 2 glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014, 123, 3478-3487.	0.6	120
5	In vivo distribution of $\beta$ 2 glycoprotein I under various pathophysiologic conditions. <i>Blood</i> , 2011, 118, 4231-4238.	0.6	113
6	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	3.5	95
7	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against $\beta$ 2 Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti- $\beta$ 2 Glycoprotein I Domain 1 to Anti- $\beta$ 2 Glycoprotein I Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 2196-2204.	2.9	94
8	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 6-12.	3.0	89
9	Patients with antiphospholipid syndrome display endothelial perturbation. <i>Journal of Autoimmunity</i> , 2010, 34, 105-110.	3.0	82
10	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 194-200.	3.0	80
11	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , 2008, 17, 938-943.	0.8	63
12	Beyond thrombosis: Anti- $\beta$ 2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 90, 76-83.	3.0	60
13	Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the $\beta$ 2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , 2012, 38, J209-J215.	3.0	58
14	$\beta$ 2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014, 55, 42-50.	3.0	52
15	Obstetric and vascular APS: Same autoantibodies but different diseases?. <i>Lupus</i> , 2012, 21, 708-710.	0.8	41
16	New insight into antiphospholipid syndrome: antibodies to $\beta$ 2 glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	1.7	40
17	Updating on the Pathogenic Mechanisms of the Antiphospholipid Antibodies-Associated Pregnancy Loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 332-337.	2.9	38
18	Immune parameters identify Italian centenarians with a longer five-year survival independent of their health and functional status. <i>Experimental Gerontology</i> , 2014, 54, 14-20.	1.2	34

#	ARTICLE	IF	CITATIONS
19	Decreased sialylation of the acute phase protein Î±1-acid glycoprotein in feline infectious peritonitis (FIP). <i>Veterinary Immunology and Immunopathology</i> , 2004, 99, 229-236.	0.5	33
20	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016, 18, 111.	1.6	32
21	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 93, 114-123.	3.0	24
22	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 67-73.	2.9	23
23	Toll-like receptor 4 and Î²2 glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014, 23, 1302-1304.	0.8	23
24	Complement Activation and Thrombin Generation by MBL Bound to Î²2-Glycoprotein I. <i>Journal of Immunology</i> , 2020, 205, 1385-1392.	0.4	16
25	Detection of red blood cell antibodies in mitogenâ€stimulated cultures from patients with hereditary spherocytosis. <i>Transfusion</i> , 2015, 55, 2930-2938.	0.8	14
26	International standards for IgG and IgM anti-Î²2 glycoprotein antibody measurement. <i>Lupus</i> , 2014, 23, 1317-1319.	0.8	13
27	Anti-Î²2-glycoprotein I ELISA assay: The influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , 2009, 101, 789-791.	1.8	11
28	Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 940-941.	0.5	11
29	Î²2 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 0271678X2098455.	2.4	8
30	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 55-67.	0.1	4
31	Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , 2009, 101, 789-91.	1.8	3
32	AB0131â€...Tissue Beta 2 glycoprotein I in Brain Ischemic Injury. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 941.3-941.	0.5	1
33	OP0060â€...Beta2GPI and TLR4 interaction on endothelial cells: A bridge between innate and adaptive immunity in APS. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 73.2-73.	0.5	0
34	A5.5â€...Antibodies against Domain I of Î²2 Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A31.3-A32.	0.5	0
35	AB1013â€...Systemic Sclerosis and Myositis Extractable Nuclear Antigen (ENA) Analysis: Profile of A Cohort of Subjects with Isolated Raynaud's Phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1135.3-1135.	0.5	0
36	AB1085â€...Empirical Approach to Investigate Raynaud's Phenomenon: The Pearl Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1263.2-1263.	0.5	0